Immunocore Holdings plc (IMCR)
Chart Events
Performance Outlook
| Previous Close | 30.50 |
| Open | 30.50 |
| Bid | 30.40 x 3000 |
| Ask | 30.77 x 900 |
| Day's Range | 30.50 - 32.60 |
| 52 Week Range | 30.00 - 61.99 |
| Volume | 45,135 |
| Avg. Volume | 50,306 |
| Market Cap | 1.401B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.50 |
- Insider Monkey
Is Immunocore Holdings plc (IMCR) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]
- GlobeNewswire
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 June 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, i
- Barrons.com
Genesco, Immunocore See Activist Action
Legion Partners reduced the number of nominees it has for footwear retailer Genesco’s board. Baker Brothers became an active investor in U.K.-based biotech Immunocore.
